| 查看: 853 | 回复: 2 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
fengyan22荣誉版主 (知名作家)
体会，期待顿悟
|
[交流]
【求助】盐酸莫西沙星原料英国药典标准
|
||
|
求助盐酸莫西沙星原料英国药典标准。。。 或者哪位权限比较高 http://medchem.dxy.cn/bbs/topic/16727438 在这帮着下来。。。 谢了 |
回复此楼» 猜你喜欢
估计是周四
已经有3人回复
-
基金啊基金
已经有3人回复
-
科研孤儿太难了
已经有15人回复
-
让我中一个面上吧！
已经有10人回复
-
言之凿凿，明天官网会通知放榜？
已经有17人回复
-
时间戳又变了
已经有17人回复
-
今天系统多次维护，明天很可能放榜！
已经有11人回复
-
时间戳变了，能看出什么问题？
已经有23人回复
-
只有每年这种时候来逛逛小木虫
已经有22人回复
-
放榜前的不淡定
已经有12人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 有没有同仁遇到 傅克酰基化反应，含溴原料会掉溴吗，（就是乙酰氯上乙酰基的反应）
已经有4人回复
- 化合物成盐酸盐
已经有12人回复
- 浓盐酸和稀盐酸加热可以溶解金银吗
已经有12人回复
- 莫西沙星质量标准问题
已经有22人回复
- 关于莫西沙星溶液稳定性的问题
已经有11人回复
- 报上去的 莫西沙星 发补了
已经有40人回复
- 研究过盐酸莫西沙星构型的朋友们，来交流一下啊。
已经有17人回复
- 【求助】盐酸莫西沙星脱色问题
已经有42人回复
- 【求助】有做过盐酸莫西沙星的吗？
已经有21人回复
- 【求助】急需莫西沙星侧链对映体或者消旋体，以及莫西沙星成品对映体，或者莫西沙星消
已经有14人回复
- 【求助】盐酸莫西沙星国外药典为何没有检查异构体？？
已经有14人回复
- 【求助】求莫西沙星侧链三个化合物的熔点及物理性质
已经有7人回复
lemonin2008
铁杆木虫 (正式写手)
- 应助: 4 (幼儿园)
- 金币: 5428.6
- 红花: 3
- 帖子: 438
- 在线: 142.2小时
- 虫号: 1065147
- 注册: 2010-07-27
- 性别: MM
- 专业: 色谱分析
3楼2010-08-31 10:49:13
lemonin2008
铁杆木虫 (正式写手)
- 应助: 4 (幼儿园)
- 金币: 5428.6
- 红花: 3
- 帖子: 438
- 在线: 142.2小时
- 虫号: 1065147
- 注册: 2010-07-27
- 性别: MM
- 专业: 色谱分析
fengyan22(金币+5):谢了 2010-09-01 23:04:13
|
----------------------- 页面 1----------------------- Browse: British Pharmacopoeia 2009 British Pharmacopoeia Volume I & II Monographs: Medicinal and Pharmaceutical Substances Moxifloxacin Hydrochloride Moxifloxacin Hydrochloride General Notices (Ph Eur monograph 2254) C H ClFN O 437.9186826-86-8 21 25 3 4 Action and use Fluoroquinolone antibacterial. Ph Eur DEFINITION 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4- oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride. Content 98.0 per cent to 102.0 per cent (anhydrous substance). PRODUCTION The production method is validated to demonstrate the satisfactory enantiomeric purity of the final product. CHARACTERS Appearance Light yellow or yellow powder or crystals, slightly hygroscopic. Solubility Sparingly soluble in water, slightly soluble in ethanol (96 per cent), practically insoluble in acetone. IDENTIFICATION (C)Crown Copyright 2006 1 ----------------------- 页面 2----------------------- IDENTIFICATION A. Specific optical rotation (see Tests). B. Infrared absorption spectrophotometry (2.2.24). Comparisonmoxifloxacin hydrochloride CRS. C. Dissolve 50 mg in 5 ml of water R, add 1 ml of dilute nitric acid R, mix, allow to stand for 5 min and filter. The filtrate gives reaction (a) of chlorides (2.3.1). TESTS Appearance of solution The solution is not more opalescent than reference suspension II (2.2.1) and not more intensely coloured than reference solution GY2 (2.2.2, Method II). If intended for use in the manufacture of parenteral dosage forms, the solution is clear (2.2.1) and not more intensely coloured than reference solution GY2 (2.2.2, Method II). Dissolve 1.0 g in 20 ml of dilute sodium hydroxide solution R. pH (2.2.3) 3.9 to 4.6. Dissolve 0.10 g in 50 ml of carbon dioxide-free water R. Specific optical rotation (2.2.7) - 125 to - 138 (anhydrous substance). Dissolve 0.200 g in 20.0 ml of a mixture of equal volumes of acetonitrile R and water R. Related substances Liquid chromatography (2.2.29). Carry out the test protected from light. Solution ADissolve 0.50 g of tetrabutylammonium hydrogen sulphate R and 1.0 g of potassium dihydrogen phosphate R in about 500 ml of water R. Add 2 ml of phosphoric acid R and 0.050 g of anhydrous sodium sulphite R, then dilute to 1000.0 ml with water R. Test solution (a)Dissolve 50.0 mg of the substance to be examined in solution A and dilute to 50.0 ml with the same solution. Test solution (b)Dilute 2.0 ml of test solution (a) to 20.0 ml with solution A. Reference solution (a)Dissolve 50.0 mg of moxifloxacin hydrochloride CRS in solution A and dilute to 50.0 ml with the same solution. Dilute 2.0 ml of this solution to 20.0 ml with solution A. Reference solution (b)Dissolve 5 mg of moxifloxacin for peak identification CRS (containing impurities A, B, C, D and E) in solution A and dilute to 5.0 ml with the same solution. Reference solution (c)Dilute 1.0 ml of test solution (a) to 100.0 ml with solution A. Dilute 1.0 ml of this solution to 10.0 ml with solution A. Column: — size: l = 0.25 m, O = 4.6 mm; — stationary phase: end-capped phenylsilyl silica gel for chromatography R (5 μm); — temperature: 45 °C. (C)Crown Copyright 2006 2 ----------------------- 页面 3----------------------- — temperature: 45 °C. Mobile phaseMix 28 volumes of methanol R and 72 volumes of a solution containing 0.5 g/l of tetrabutylammonium hydrogen sulphate R, 1.0 g/l of potassium dihydrogen phosphate R and 3.4 g/l of phosphoric acid R. Flow rate1.3 ml/min. DetectionSpectrophotometer at 293 nm. Injection10 μl of test solution (a) and reference solutions (b) and (c). Run time2.5 times the retention time of moxifloxacin. Identification of impuritiesUse the chromatogram supplied with moxifloxacin for peak identification CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities A, B, C, D and E. Relative retentionWith reference to moxifloxacin (retention time = about 14 min): impurity A = about 1.1; impurity B = about 1.3; impurity C = about 1.4; impurity D = about 1.6; impurity E = about 1.7. System suitabilityReference solution (b): — resolution: minimum 1.5 between the peaks due to moxifloxacin and impurity A; — the chromatogram obtained is similar to the chromatogram supplied with moxifloxacin for peak identification CRS. Limits: — correction factors: for the calculation of content, multiply the peak areas of the following impurities by the corresponding correction factor: impurity B = 1.4; impurity E = 3.5; — impurities A, B, C, D, E: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.1 per cent); — unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.10 per cent); — total: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (c) (0.3 per cent); — disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (c) (0.05 per cent). Water (2.5.12) Maximum 4.5 per cent, determined on 0.200 g. Sulphated ash (2.4.14) Maximum 0.1 per cent, determined on 1.0 g in a platinum crucible. ASSAY Liquid chromatography (2.2.29) as described in the test for related substances with the following modification. InjectionTest solution (b) and reference solution (a). Calculate the percentage content of C H ClFN O from the declared content of moxifloxacin 21 25 3 4 hydrochloride CRS. (C)Crown Copyright 2006 3 ----------------------- 页面 4----------------------- STORAGE In an airtight container , protected from light. LABELLING The label states, where applicable, that the substance is suitable for use in the manufacture of parenteral dosage forms. IMPURITIES Specified impuritiesA, B, C, D, E. A. R = R = F: 1-cyclopropyl-6,8-difluoro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6- ′ yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, B. R = R = OCH : 1-cyclopropyl-6,8-dimethoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b] ′ 3 pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, C. R = F, R = OC H : 1-cyclopropyl-8-ethoxy-6-fluoro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3, ′ 2 5 4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, D. R = OCH , R = F: 1-cyclopropyl-8-fluoro-6-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo ′ 3 [3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, E. R = F, R = OH: 1-cyclopropyl-6-fluoro-8-hydroxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3, ′ 4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid. Ph Eur (C)Crown Copyright 2006 4 ----------------------- 页面 5----------------------- Browse: British Pharmacopoeia 2009 British Pharmacopoeia Volume I & II Monographs: Medicinal and Pharmaceutical Substances Moxisylyte Hydrochloride Moxisylyte Hydrochloride General Notices C H NO ,HCl315.8964-52-3 16 25 3 Action and use Alpha-adrenoceptor antagonist. Preparation Moxisylyte Tablets DEFINITION Moxisylyte Hydrochloride is 4-(2-dimethylaminoethoxy)-5-isopropyl-2-methylphenyl acetate hydrochloride. It contains not less than 99.0% and not more than 101.0% of C H NO ,HCl, 16 25 3 calculated with reference to the dried substance. CHARACTERISTICS A white, crystalline powder. Freely soluble in water and in chloroform; soluble in ethanol (96%); practically insoluble in ether and in petroleum spirit. IDENTIFICATION A. The infrared absorption spectrum, Appendix II A, is concordant with the reference spectrum of moxisylyte hydrochloride (RS 238). B. Yields reaction A characteristic of chlorides, Appendix VI. TESTS Acidity pH of a 5% w/v solution, 4.5 to 5.5, Appendix V L. (C)Crown Copyright 2006 1 |
2楼2010-08-31 10:48:23
